Skip to main content
. 2021 Dec 6;7(4):00457-2021. doi: 10.1183/23120541.00457-2021

TABLE 1.

Characteristics and forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio z-scores of each cohort included in the age groups

Cohorts Nations Age groups n Age # FEV1 FVC FEV1/FVC ratio
GLI fit # Mean-centred GLI fit # Mean-centred GLI fit # Mean-centred
ALSPAC+ UK >5–10 6804 8.7±0.3 0.04±1.00 −0.09±1.02 −0.06±1.02 −0.02±1.04 0.15±1.02 −0.10±1.07
>15–20 4519 15.5±0.3 −0.68±1.29 −0.04±1.26 −1.02±1.29 0.04±1.25 0.61±1.16 −0.14±1.21
>20–25 3731 24.5±0.8 −0.52±1.01 0.06±1.00 −0.37±1.02 0.13±0.98 −0.27±0.94 −0.1±0.98
BAMSE+ Sweden >5–10 1832 8.3±0.5 0.47±0.94 −0.06±0.94 0.59±0.90 −0.00±0.91 −0.27±0.87 −0.07±0.89
>15–20 2052 16.7±0.4 0.06±0.92 −0.11±0.94 0.16±0.92 −0.01±0.92 −0.19±0.93 −0.15±0.96
>20–25 2032 22.5±0.5 −0.23±0.85 −0.03±0.86 −0.12±0.85 0.07±0.85 −0.20±0.88 −0.15±0.90
Generation R+ Netherlands >5–10 4738 9.8±0.3 0.19±0.93 −0.04±0.93 0.21±0.89 0.02±0.92 −0.08±0.90 −0.01±0.96
>10–15 3869 13.6±0.4 −0.15±1.01 −0.06±0.93 −0.09±0.98 0.04±0.99 −0.13±0.92 0.00±1.02
HUNT1 Norway >10–15 2705 14.1±0.6 −0.23±1.11 −0.02±1.11 −0.19±1.10 0.01±1.10 −0.07±1.03 −0.05±1.03
>15–20 5256 17.1±1.3 −0.12±1.04 −0.03±1.04 −0.09±1.01 0.02±1.01 −0.08±0.98 −0.08±0.98
HUNT3 Norway >10–15 2792 14.1±0.6 0.01±1.03 −0.01±1.03 0.10±1.05 0.04±1.05 −0.15±1.02 −0.22±1.02
>15–20 4363 16.9±1.2 0.09±0.99 −0.04±0.99 0.19±1.01 0.03±1.01 −0.19±0.98 −0.09±0.97
INMA+ Spain 1–5 704 4.5±0.2 −0.59±1.20 −0.01±1.21 −0.53±1.23 0.01±1.25 −0.03±0.95 −0.03±0.97
>5–10 1277 7.4±0.6 0.21±0.98 −0.01±0.99 0.40±0.95 0.01±0.96 −0.34±0.99 −0.03±1.00
>5–10 476 9.3±0.9 −0.02±1.07 −0.03±1.05 0.17±1.04 −0.00±1.01 −0.21±0.98 −0.06±0.95
>10–15 988 11.2±0.6 −0.20±1.00 −0.01±1.03 −0.06±1.03 0.02±1.04 −0.25±0.95 −0.04±1.01
>10–15 266 14.6±0.2 0.04±0.94 −0.04±0.95 −0.04±0.98 −0.02±0.95 0.13±0.87 −0.03±0.90
>15–20 120 17.7±0.3 −0.34±0.92 −0.03±0.89 −0.32±0.98 0.07±0.94 −0.04±0.99 −0.15±1.02
IoW UK >5–10 980 9.9±0.3 0.37±0.97 −0.04±0.99 0.16±0.88 0.02±0.88 0.33±0.96 −0.09±1.01
>15–20 836 17.8±0.6 0.30±0.92 −0.15±0.99 0.14±0.85 0.01±0.93 0.22±1.07 −0.21±1.11
LEAD Austria >5–10 451 8.4±1.0 0.46±1.27 −0.07±0.99 0.31±1.26 0.10±0.92 0.35±1.17 −0.31±1.13
>10–15 526 12.3±1.5 0.01±1.03 −0.35±1.02 −0.19±0.97 −0.14±0.98 0.36±0.95 −0.39±1.04
>15–20 540 17.4±1.4 −0.05±1.07 −0.36±1.01 −0.22±1.08 −0.11±0.97 0.30±1.08 −0.44±1.12
>20–25 703 22.5±1.4 −0.13±1.04 −0.42±0.92 −0.31±1.09 −0.16±0.92 0.22±0.99 −0.46±1.02
Lifelines Netherlands >15–20 2556 18.9±0.8 −0.42±0.91 −0.06±0.92 −0.34±0.90 0.03±0.89 −0.19±0.98 −0.14±1.01
>20–25 5028 23.3±1.5 −0.42±0.90 −0.06±0.91 −0.29±0.89 0.05±0.87 −0.23±0.96 −0.16±0.96
MAAS+ UK >5–10 778 8.0±0.2 0.15±0.93 −0.07±0.10 0.26±0.90 0.00±0.94 −0.24±0.89 −0.11±0.93
>10–15 778 11.5±0.5 −0.12±0.95 −0.05±1.00 −0.18±1.12 0.05±1.12 0.14±1.03 −0.15±1.10
>15–20 566 16.0±0.6 −0.26±0.95 −0.06±1.05 −0.43±0.90 0.03±0.96 0.31±1.02 −0.16±1.11
>15–20 504 19.4±0.8 −0.24±0.87 −0.04±0.95 −0.40±0.90 0.10±0.90 0.26±0.97 −0.24±1.04
OLIN Sweden >15–20 1470 18.2±0.5 −0.06±1.01 −0.04±1.01 0.08±1.06 0.01±1.03 −0.28±0.93 −0.07±0.96
PIAMA+ Netherlands >5–10 1058 8.1±0.3 0.54±0.88 −0.05±0.91 0.29±0.88 0.00±0.90 0.42±1.06 −0.09±1.09
>10–15 1267 12.7±0.4 −0.56±0.84 −0.04±0.86 −0.37±0.85 −0.01±0.86 −0.37±0.87 −0.04±0.89
>15–20 720 16.4±0.2 −0.19±0.86 −0.07±0.88 0.02±0.86 −0.00±0.82 −0.40±0.92 −0.10±0.94
SEATON+ UK 1–5 446 4.9±0.2 0.17±0.96 −0.03±0.95 −0.13±1.05 −0.00±1.05 0.08±0.93 −0.04±0.95
>10–15 430 10.3±0.2 −0.12±1.10 −0.06±1.09 −0.24±1.04 −0.01±1.04 0.15±0.93 −0.08±0.96
>15–20 534 15.1±0.3 −0.36±1.00 −0.04±1.00 −0.77±1.02 0.01±1.00 0.83±1.09 −0.10±1.13
SUS Denmark >15–20 2294 18.9±1.3 −0.29±0.90 −0.01±0.90 −0.33±0.88 0.05±0.88 0.01±1.00 −0.09±1.00

Data are expressed as mean±sd. GLI: Global Lung Function Initiative. #: based on the whole group of participants; : based on non-asthmatic, asymptomatic lifelong nonsmokers; +: they are longitudinal cohorts with repeated measurement at different age.